Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Pharmacoepidemiology of statins.

Bezin J, Moore N.

Therapie. 2019 Jan 18. pii: S0040-5957(19)30008-3. doi: 10.1016/j.therap.2019.01.004. [Epub ahead of print]

PMID:
30704765
2.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

3.

Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Lozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug.

4.

Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy.

Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D, Gaddi A, Vaccheri A, Montanaro N.

Eur J Clin Pharmacol. 2008 Apr;64(4):425-32. doi: 10.1007/s00228-007-0428-8. Epub 2008 Jan 5.

PMID:
18176802
5.

[Benefits and risks for primary prevention with statins in the elderly].

Joseph JP, Afonso M, Berdaï D, Salles N, Bénard A, Gay B, Bonnet F.

Presse Med. 2015 Dec;44(12 Pt 1):1219-25. doi: 10.1016/j.lpm.2015.09.015. Epub 2015 Nov 14. French.

PMID:
26585744
6.

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.

Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X.

Cochrane Database Syst Rev. 2018 Nov 19;11:CD012502. doi: 10.1002/14651858.CD012502.pub2. Review.

PMID:
30480766
7.

Statins and elderly: from clinical trials to daily practice.

Verdoia M, Galasso G, Filardi PP, De Luca G.

Curr Vasc Pharmacol. 2018 Jun 28. doi: 10.2174/1570161116666180628145723. [Epub ahead of print]

PMID:
29956633
8.

Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.

Izquierdo-Palomares JM, Fernandez-Tabera JM, Plana MN, Añino Alba A, Gómez Álvarez P, Fernandez-Esteban I, Saiz LC, Martin-Carrillo P, Pinar López Ó.

Cochrane Database Syst Rev. 2016 Nov 26;11:CD009462. Review.

PMID:
27888640
9.

Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.

Sanders RD, Nicholson A, Lewis SR, Smith AF, Alderson P.

Cochrane Database Syst Rev. 2013 Jul 3;(7):CD009971. doi: 10.1002/14651858.CD009971.pub2. Review.

PMID:
23824754
10.

Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.

Bruckert E, Ferrières J.

Arch Cardiovasc Dis. 2014 Mar;107(3):188-200. doi: 10.1016/j.acvd.2014.01.011. Epub 2014 Mar 7.

11.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019. doi: 10.1002/14651858.CD005019.pub4. Review.

PMID:
24470059
12.

Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries.

McAfee AT, Rodríguez LA, Goettsch WG, González-Pérez A, Johansson S, Ming EE, Wallander MA, Herings RM.

Minerva Cardioangiol. 2010 Dec;58(6):611-22.

PMID:
21135803
13.

Statins for the primary prevention of cardiovascular disease.

Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816. doi: 10.1002/14651858.CD004816.pub5. Review.

14.
15.

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

Evans M, Rees A.

Drug Saf. 2002;25(9):649-63. Review.

PMID:
12137559
16.

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD.

Drug Saf. 2010 Mar 1;33(3):171-87. doi: 10.2165/11319380-000000000-00000. Review.

PMID:
20158283
17.

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 May 31;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2. Review.

PMID:
24880031
18.

The causes and effects of socio-demographic exclusions from clinical trials.

Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, Dieppe P.

Health Technol Assess. 2005 Oct;9(38):iii-iv, ix-x, 1-152. Review.

19.

A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M.

Drugs. 2013 Jul;73(10):1025-54. doi: 10.1007/s40265-013-0072-9. Review.

PMID:
23754124

Supplemental Content

Support Center